

## ChIVPP (based on LY09 Trial)

**INDICATION:** Hodgkin's lymphoma where anthracyclines-based chemotherapy is contraindicated

### Prior to a course of treatment

- Check FBC - patient should have adequate bone marrow reserve i.e neutrophils > 1.5, platelets > 100 unless cytopaenia is due to disease, e.g marrow infiltration, splenomegaly
- Check recent renal and hepatic function are within normal limits - *if not discuss with consultant and see dose modification*
- If appropriate discuss possibility of pregnancy with female patients and need for contraception with both male and female patients. Discuss risk of infertility - offer semen cryopreservation to male patients
- Written consent for course

### Prior to each cycle

- Medical review of fitness for chemotherapy – exclude active infection, major changes in organ function
- Check FBC, U&Es, creat, LFTs - neutrophils should be > 1.5, platelets > 100 - *see dose modifications*

### On day 8 of each cycle

- Medical review of fitness for chemotherapy – exclude active infection, major changes in organ function
- Check FBC – *see dose modifications*

|                 |                         |          |              |
|-----------------|-------------------------|----------|--------------|
| Chlorambucil *  | 6mg/m <sup>2</sup>      | PO       | days 1-14    |
| Vinblastine     | 6mg/m <sup>2</sup>      | IV bolus | days 1 and 8 |
| Procarbazine ** | 100mg/m <sup>2</sup> od | PP       | days 1-14    |
| Prednisolone    | 40mg/m <sup>2</sup>     | PO       | days 1-14    |

### Repeat cycle every 28 days for up to 6 cycles

\* 2mg tablets      \*\* 50mg capsules

**NB:** Patient must be advised to avoid alcohol while taking procarbazine

|                                       |   |
|---------------------------------------|---|
| <b>Prophylaxis for acute emesis</b>   | None required   |
| <b>Prophylaxis for delayed emesis</b> | Metoclopramide for 14 days  |
| <b>Other medications</b>              | Allopurinol 300mg od for 14 days with cycle 1<br>Anti-infective prophylaxis according to local policy |

### Dose modification (day 1) for leucopenia and infection

- |   |   |
|---|---|
| • Neutrophils > 1.5 on day 1                | Proceed with 100% doses   |
| • Neutrophils < 1.5 on day1                 | Defer treatment for 1-2 weeks                                   |
| • Neutrophils remains <1.5 despite delay    | Consider GCSF for up to 1 week – <i>discuss with consultant</i> |
| • Neutrophils fails to recover despite GCSF | ChIVPP may be inappropriate – <i>discuss with consultant</i>    |

- If treatment is delayed > 1week, or >1 delay, or an episode of neutropenic sepsis Consider GCSF prophylaxis with subsequent cycles – *discuss with consultant*
- If further delay or neutropenic sepsis despite GCSF Consider proceeding at 50-75% chlorambucil, vinblastine and procarbazine – *discuss with consultant*

**Dose modification (day 1) for thrombocytopenia**

- Platelets >100 on day 1 Proceed at 100% doses
- Platelets < 100 on day 1 Delay cycle 1-2 weeks
- Platelets remain < 100 despite delay Consider proceeding at 50-75% dose chlorambucil, vinblastine and procarbazine or proceed at 100% dose with platelet support - *discuss with consultant*

**Dose modification (day 8) for neutropenia and thrombocytopenia**

- Neutrophils > 1.5 and plats > 100 *Proceed at 100% doses*
- Neutrophils 1.0 – 1.5 or plats 50 -100 Consider 100% dose with GCSF support or proceed with 50% vinblastine and chlorambucil & stop procarbazine – *discuss with consultant*
- Neutrophils < 1.0 or plats < 50 Consider proceeding with 100% doses and GCSF support or omit vinblastine. Stop chlorambucil and procarbazine – *discuss with consultant*

**Dose modification for vinblastine neurological toxicity**

- If grade 2 motor (*mild objective weakness interfering with function but not with activities of daily living*) or grade 3 sensory neurological toxicity (*sensory loss or paresthesia interfering with activities of daily living*) appears, reduce the dose to 3mg/m<sup>2</sup>.
- If toxicity increases despite dose reduction, stop vinblastine.

**Unavailability or intolerance of procarbazine**

Consider using etoposide 100mg od PO for 5 days

**Dose modification for renal dysfunction**

- If serum creatinine > 180µmol/l Consider procarbazine dose reduction – *discuss with consultant*

**Dose modification for liver dysfunction**

- Bilirubin 26 - 57µmol/l or AST/ALT 60-180 Use 50% dose vinblastine
- Bilirubin > 57µmol/l and normal AST/ALT Use 50% dose vinblastine
- Bilirubin >57µmol/l and AST/ALT >180 Omit vinblastine
- In severe liver dysfunction consider reduced dose of chlorambucil

**ChIVPP Toxicities**

|   |  |
|---|--|
| Neutropenic sepsis                        | Nausea (moderate) – but severe with alcohol & procarbazine |
| Thrombocytopenia                          | Amenorrhoea & infertility (offer semen cryopreservation)   |
| Hyperglycaemia                            | Alopecia   |
| Peripheral neuropathy                     | Autonomic neuropathy – constipation, ileus                 |
| Rash (photosensitivity with procarbazine) | Second malignancies (late)                                 |

|                    |   |
|--------------------|---|
| <b>Written by</b>  | Dr MP Macheta, Consultant Haematologist |
| <b>Date</b>        | July 2013                               |
| <b>Review date</b> | July 2015                               |